

Please complete all required sections to allow your request

ADALIMUMAB/ETANERCEPT/GOLIMUMAB/INFLIXIMAB for Ankylosing Spondylitis SPECIAL AUTHORIZATION REQUEST FORM

Patients may or may not meet eligibility requirements as established

to be processed. by Alberta Government sponsored drug programs.									
				COVERAGE TYPE:					
PATIENT LAST NAME		FIRST NAM	FIRST NAME			INITIAL	Alberta Blue Cross		
DATE OF BIRTH: Year / Month / Day ALBERTA PERSONAL			PERSONAL HEAL	ALTH NUMBER					
STREET ADDRESS		CITY			PROV	POSTAL CODE IDENTIF		IFICATION/CLIENT/COVERAGE No:	
PRESCRIBER INFORMATION									
PRESCRIBER LAST NAME FIRST NAME INITIAL PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION									
				CPSA ACO REGISTRATION NO.					
STREET ADDRESS				CARNA ADA+C					
				PHONE: FAX:					
CITY , PROVINCE									
POSTAL CODE				FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED					
Please provide the following information for ALL requests:									
Diagnosis: Current Indicate requested drug: Dosage:									
				weight (kg):		Adalimumab		Dosage.	
Ankylosing Spondylitis (meeting modified NY criteria					Etanercept			Dosing frequency:	
Other (please SPECIFY):						Golimumab			
Please provide the following information for all NEW requests:									
Previous medications utilized: Have two or more NSAIDs been tried for a minimum of 4 weeks each at maximum tolerated or recommended doses?									
	Please SPECIFY the NSAID		ation on	ation, and response					
NSAID #1:				ation, an	u respon	30			
NSAID #2:									
Other, please SPECIFY: Please provide the following information for all NEW* requests: Please provide the following information for all									
					RENEWAL requests:				
BASDAI#I		Date:		BASDAI			Date:		
BASDAI #2:		Date:		Spinal pain VAS (cm)			Date:		
Spinal Pain VAS #1 (cm):		Date:		Place provide reason if a switch			to a d	lifferent hiologic agent is requested:	
Spinal Pain VAS #2 (cm):		Date:		Please provide reason if a switch to a different biologic agent is requested:					
* New requests for patients currently maintained on the requested biologic require pre-treatment scores. Scores 1 and 2 for each parameter must be at least 8 weeks apart.				Note: Patients will not be permitted to switch back to a previously trialed biologic agent if they were deemed unresponsive to therapy.					
Additional information relating to request:									
PRESCRIBER'S SIGNATURE		DATE		 AI 10 	 Please forward this request to: Alberta Blue Cross, Clinical Drug Services 10009-108 Street NW, Edmonton, Alberta T5J 3C5 FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas 				
	ONCE YOUR REQUEST HAS			ED, PLE	ASE DO	NOT MAIL OR F	RE-FA	X YOUR REQUEST.	
he information on this form eceive a benefit, product of	is being collected and pursuant to sections 20, 21 and 22 health service. If you have any questions regarding the c	2 of the Health Information Act collection or use of this information	, and sections 33 and 34 of the tion, please contact an Alber	he Freedom of I ta Blue Cross p	nformation and F rivacy matters re	Protection of Privacy Act, for the presentative toll-free at 1-855-	ne purposes -498-7302 c	of determining or verifying eligibility to participate in a program or or write to Privacy Matters, Alberta Blue Cross, 10009 - 108 Street,	